公开(公告)号：US20240166647A1

公开(公告)日：2024-05-23

申请号：US18279225

申请日：2022-03-03

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Shaomeng Wang ,  Tianfeng Xu ,  Dimin Wu ,  Zhixiang Chen ,  Xin Han ,  Weiguo Xiang ,  Rohan Rej ,  Angelo Aguilar ,  Longchuan Bai

IPC分类号： C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04 ,  C07D498/14

CPC分类号： C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04 ,  C07D498/14

摘要： The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.

公开(公告)号：US20240150360A1

公开(公告)日：2024-05-09

申请号：US18279232

申请日：2022-03-03

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Shaomeng Wang ,  Zhixiang Chen ,  Dimin Wu ,  Mi Wang

IPC分类号： C07D487/04 ,  C07D401/04 ,  C07D471/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D401/04 ,  C07D471/04 ,  C07D519/00

摘要： The present disclosure relates to compounds of Formula (I), and the pharmaceutically


A—(CH2)m—X—Y—Z—B1  I,

acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer).

公开(公告)号：US20240190880A1

公开(公告)日：2024-06-13

申请号：US18279236

申请日：2022-03-04

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Shaomeng Wang ,  Zhixiang Chen ,  Rohan Rej ,  Dimin Wu ,  Jianfeng Lu ,  Biao Hu ,  Mingliang Wang ,  Ranjan Kumar Acharyya

IPC分类号： C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  C07D519/00

摘要： The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B 1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating preventing a condition or disorder responsive to the degradation of estrogen receptor protein (e.g., cancer).